EC authorises contract with CureVac to secure another vaccine

It will allow the Commission to buy up to 405 million doses

Photo: EU Ursula von der Leyen.

A few days after its contract with BioNTech and Pfizer, the Commission will authorise on Tuesday a new contract to secure another Covid-19 vaccine. This will allows us to buy up to 405 million doses of a vaccine produced by the European company CureVac, said EC President Ursula von der Leyen in a statement on Monday afternoon noting that “We need a safe and effective vaccine to end this pandemic”.

Von der Leyen recalled that earlier this year, the EC have provided funding to CureVac, together with the European Investment Bank, as to support the development of this vaccine. Saying that now, progress is tangible she specified that if the vaccine has proven safe and effective against Covid-19, every Member State will receive the vaccine at the same time, on a pro-rata basis, and under the same conditions.

The EC President pointed out that this is the fifth contract with a pharmaceutical company for our Covid-19 vaccine portfolio, and the sixth is underway as the Commission has already concluded exploratory talks with Moderna. We hope to finalise the contract soon, she stressed.

"We do not know at this stage, which vaccines will end up being safe and effective. The European Medicines Agency EMA will authorise them only after a robust assessment. This is why we need to have a broad portfolio of vaccines based on very different technologies. In parallel, we are working with COVAX to provide access to vaccines for low- and middle-income countries. Thus, we want to ensure that all have access rapidly to safe and effective vaccines", von der Leyen underscored.

 

Similar articles